Plerixafor – Primary Usage, Stem Cells, and Availability for R&D Purposes

Plerixafor – Primary Usage, Stem Cells, and Availability for R&D Purposes

PlerixaforPlerixafor is a new compound that can be used as an effective drug to cure cancer patients. This drug is an immunostimulant and is used to increase hematopoietic stem cells in patients suffering from cancer. The stem cells are then transplanted into the patients. Initially, this drug was developed to help HIV patients because it can block CXCR4, which is a chemokine receptor that helps to create certain strains in AIDS patients. However, researches for Plerixafor as an HIV drug were terminated because it was not possible to take this medicine orally. Also, this medicine caused serious cardiac disturbances in AIDS patients. However, recent studies established the safe usage of this drug for treating cancer patients.

Uses of Plerixafor

The primary usage of Plerixafor is to mobilize peripheral blood stem cells that help in transplantation of hematopoietic stem cells. A major stimulating factor is G-CSF but it proves to be ineffective in many patients. However, by using G-CSF with Plerixafor, production of hematopoietic stems cells can be increased to produce enough stem cells to successfully transplant into patients.

Plerixafor has been approved for treating patients suffering with multiple myeloma and lymphoma.

Further research for Plerixafor

Recently, medical studies have suggested that Plerixafor can also be used to produce stem cells other than the hematopoietic stem cells. At Imperial College, researchers used this drug on mice to generate mesenchymal stem cells and endothelial progenitor cells. They found that Plerixafor in combination with VEGF (Vascular endothelial growth factor) could produce a variety of stem cells.

In various medical experiments on mice, Plerixafor was found to reduce metastasis and inhibit glioblastoma in mice.  This drug can cause serious side effects in pregnant women as it has shown teratogenic effects in pregnant animals.

Plerixafor FDA Approval

On December 15th, 2008, the US Food and Drug Administration (FDA) approved Plerixafor as an orphan drug that can be used to mobilize and produce hematopoietic stem cells for transplantation in patients suffering from cancer. The efficacy and safety of Plerixafor as a drug for cancer patients in combination with G-CSF was tested in two placebo-controlled studies and it was found that this drug is efficient in increasing the production of hematopoietic stem cells and is safe for usage in controlled measures.

Availability of Plerixafor

This new molecule is available for R&D purposes from LGM Pharma. Inquire about Plerixafor prices, availability, delivery, purity and more.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service